Moderate

Focal segmental glomerulosclerosis (FSGS)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A podocyte-injury pattern (not a single disease) causing focal (some glomeruli) and segmental (part of the tuft) sclerosis. A leading cause of nephrotic syndrome and ESKD, especially in adults and people of African ancestry (APOL1 risk variants). Primary (immune/permeability-factor mediated, abrupt nephrotic syndrome) vs secondary (adaptive hyperfiltration: obesity, reflux, reduced nephron mass, sickle cell; or drug/virus-associated: pamidronate, interferon, anabolic steroids, HIV). Often has haematuria, hypertension and impaired GFR, and is more steroid-resistant than minimal change — distinguishing primary (immunosuppress) from secondary (RAS blockade + treat cause) is central.

Red flags

  • Collapsing variant with rapid GFR loss — consider HIV, severe disease; poor prognosis
  • Steroid-resistant nephrotic syndrome with progressive CKD
  • Thromboembolism/infection complicating nephrotic state
  • AKI superimposed (overdiuresis, drug toxicity)
  • Mislabelling secondary FSGS as primary and giving futile/harmful immunosuppression

Assessment

Differential diagnosis

  • Minimal change disease (younger, fully steroid-responsive, normal GFR/BP)
  • Membranous nephropathy, diabetic nephropathy
  • Secondary FSGS (obesity/hyperfiltration, reflux nephropathy, reduced nephron mass, sickle cell)
  • HIV-associated nephropathy (collapsing FSGS)
  • Hypertensive nephrosclerosis

Investigations

  • Urine PCR/ACR + microscopy (proteinuria often nephrotic-range; may have haematuria)
  • Serum albumin, U&E/creatinine/eGFR, lipids, BP
  • HIV serology (collapsing variant), consider parvovirus/other; drug history (bisphosphonates, anabolic steroids, interferon)
  • Immunology to exclude mimics (ANA, complement, anti-PLA2R)
  • APOL1 context in at-risk ancestry (research/specialist); renal ultrasound (kidney size/scarring)
  • Renal biopsy for diagnosis and to judge primary vs secondary (degree of foot-process effacement on EM: diffuse in primary, segmental in secondary)

Management

  • Biopsy to confirm and determine primary vs secondary (clinical course + EM foot-process effacement guide this)
  • All patients: maximal supportive renoprotection — ACEi/ARB to reduce proteinuria, BP control, SGLT2 inhibitor, statin, sodium restriction, weight management
  • Primary FSGS with nephrotic syndrome: immunosuppress with high-dose corticosteroids as first-line induction; calcineurin inhibitor for steroid-resistant/intolerant disease
  • Secondary/adaptive FSGS: do NOT immunosuppress — treat the underlying cause (weight loss, stop offending drug, ART for HIV) plus RAS blockade
  • Manage nephrotic complications (oedema, VTE risk, infection) as per nephrotic syndrome
  • Monitor response (proteinuria reduction) and eGFR; escalate steroid-sparing agents (CNI, MMF, rituximab in selected cases) via nephrology for resistant primary disease
  • Plan for CKD trajectory; counsel on recurrence risk post-transplant in primary FSGS

Drugs & doses

Ramipril 2.5-10 mg PO once daily OR losartan 50-100 mg PO once daily (anti-proteinuric; all FSGS) [verify local dose]
Dapagliflozin 10 mg PO once daily (kidney protection/proteinuria)
Atorvastatin 20-40 mg PO once daily
Primary FSGS induction: prednisolone 1 mg/kg/day PO (max 60-80 mg) for up to 8-16 weeks then taper [verify local dose]
Calcineurin inhibitor (tacrolimus or ciclosporin) for steroid-resistant/dependent primary FSGS — specialist-initiated, monitor levels [verify local dose]
Mycophenolate mofetil or rituximab in selected resistant cases (specialist) [verify local dose]
Furosemide 40-80 mg PO/IV for oedema; VTE prophylaxis if severely hypoalbuminaemic [verify local dose]

Disposition

Nephrology outpatient management with biopsy-directed therapy; admit for severe nephrotic complications, AKI or rapid decline. Long-term CKD surveillance and transplant counselling.

Complications & pitfalls

  • Progression to ESKD (one of the commonest glomerular causes of kidney failure)
  • Steroid/immunosuppression toxicity
  • Nephrotic complications: VTE, infection, hyperlipidaemia
  • Recurrence in renal allograft (primary FSGS) — can be immediate and severe
  • Resistant hypertension

Exam pearls

  • The pivotal clinical decision is primary vs secondary FSGS: primary = abrupt full nephrotic syndrome with diffuse foot-process effacement on EM -> immunosuppress; secondary/adaptive = slower, sub-nephrotic, segmental effacement -> treat the cause + RAS blockade, do NOT immunosuppress.
  • FSGS is more steroid-resistant than minimal change — allow a longer steroid course (up to ~16 weeks) before declaring resistance in primary disease.
  • Consider HIV (collapsing FSGS) and APOL1-related risk in patients of African ancestry.
  • Primary FSGS can recur in a transplant within hours-days due to a circulating permeability factor — flag for the transplant team.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.